Please assess the completion status of the following clinical trial:

Trial Title: Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus, using already metformin (850 or 1000 mg twice daily) for at least 2 months prior to screening visit or type 2 diabetes switched to metformin at least 3 months prior to randomisation visit~* HbA1c ≥6.5 % if on antidiabetic montherapy or HbA1c ≥ 6.0 if on two antidiabetic drugs - Age of 18 - 75 years~* Male and female patients (females of child bearing potential must be using adequate contraceptive precautions)~* Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit~* Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form.~Exclusion Criteria:~* Any other form of diabetes mellitus than type 2 diabetes mellitus~* Use of insulin, glitazone, gliptin or SGLT-2 inhibitor within the past 2 months~* HbA1c \> 10.5% if on antidiabetic monotherapy and \> 9.5% if on two antidiabetic drugs~* Fasting plasma glucose \> 240 mg/dl~* Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 6 months prior to study inclusion~* UACR ≥ 300 mg/g (early morning spot urine)~* Estimated GFR (eGFR) \< 60 ml/min/1.73m²~* Uncontrolled arterial hypertension (blood pressure ≥ 180/110 mmHg)~* Congestive heart failure NYHA stage III and IV~* Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmacokinetics of study drugs~* Significant laboratory abnormalities such as serum Glutamate-Oxaloacetate-Transaminase (SGOT) or serum Glutamate-Pyruvate-Transaminase (SGPT) levels more than 3 x above the upper limit of normal range~* Drug or alcohol abuses~* Pregnant or breast-feeding patients~* Use of loop diuretics~* History of repetitive urogenital infection per year~* Body mass index \> 40 kg/m²~* Triglyceride levels \> 1000 mg/dl~* High density lipoprotein (HDL)-cholesterol levels \< 25 mg/dl~* Any patient currently receiving chronic (\>30 consecutive days) treatment with an oral corticosteroid~* Patients being treated for severe auto immune disease e.g. lupus~* Participation in another clinical study within 30 days prior to visit 1~* Individuals at risk for poor protocol or medication compliance~* Subject who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin and Linagliptin (Type: ACTIVE_COMPARATOR): After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
- Metformin and Insulin sc (Type: ACTIVE_COMPARATOR): Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).

Based on this trial design, predict the completion outcome and termination type (if applicable).